Home Add to Favorite Contact Submit  
           29 October, 2020


    
Category:  Press » Nanotechnology

 

Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules

Popularity:
         Views: 1121
2007-08-28 16:16:18     
Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel RNA interference-based therapeutics, announced today that the Company has filed a patent application covering a number of novel chemical modifications that confer to the siRNA molecule stability and excellent penetration into the human cells tested.

"With the submission of this patent application, we believe we have provided significant additional protection for our pipeline program," said Daniel Zurr, President and CEO of Quark. "Filing of this patent application marks a significant step in our efforts to solidify our position as a leader in the RNAi therapeutics space, as the new structures allow us more flexibility with regard to intellectual property. We believe our future siRNA therapeutics will be less dependent on in-licensed rights to RNAi technology. This patent application adds the element of structural design to our expertise in identifying clinically attractive drug targets using a proprietary discovery platform and local or systemic delivery."

The patent application relates to new classes of chemically modified siRNA structures that have been tested in cell culture and have demonstrated enhanced stability, silencing activity, and cell penetration. Several new molecules are currently in preclinical testing. This research is part of Quark's program to develop novel synthetic siRNA patterns with drug-like properties as well as improved targeted delivery systems.

Currently, Quark owns or controls 30 issued U.S. and European patents, and has 200 patent applications pending, covering its technology, drug candidates, target genes and pipeline products.

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing drug candidates that work through the recently discovered cellular mechanism known as RNA interference, or RNAi. Quark is able to discover novel therapeutic targets based on its proprietary gene discovery platform, BiFAR(TM). This, combined with its ability to design and successfully deliver synthetic molecules of the new class of RNAi therapeutics known as small-interfering RNA, or siRNA, to specific organs in the body, enables the Company to rapidly develop drug candidates. Quark has two internally discovered and developed lead candidates: RTP801i-14 in Phase 1 clinical trial for the treatment of wet age-related macular degeneration, and AKIi-5 for the prevention of acute renal failure. The Company has out-licensed certain siRNA drug candidates to Pfizer on an exclusive worldwide basis. These drug candidates are designed to inhibit Quark's proprietary target gene RTP801, including RTP801i-14. Quark has, in addition, a product candidate portfolio of RNAi therapeutics based on novel targets and therapeutic concepts discovered using BiFAR(TM) and designed for the treatment of oxidative stress associated diseases of the inner ear, lungs and additional organs of the body.

Quark is headquartered in Fremont, California and operates research and development facilities in Boulder, Colorado and Ness-Ziona, Israel. Additional information is available on the Company website at http://www.quarkpharma.com.

Forward-looking statement

Various statements in this release concerning the Company's future expectations, plans and prospects, including its intention to publicly offer shares of its common stock, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to fluctuations in our stock price, as well as those risks more fully discussed in the "Certain Factors That May Affect Future Results" section of the Company's most recent Quarterly Report on Form 10-Q on file with the Securities and Exchange Commission. In addition, any forward- looking statements represent the Company's views only as of today and should not be relied upon as representing its views as of any subsequent date. The Company does not assume any obligation to update any forward-looking statements.

Specialized in: Quark Pharmaceuticals
URL: http://www.quarkpharma.com
Print press release      Bookmark this page
Related Press releases 
AngelMD Venture Capital Fund Invests in Leading Bone Biologic Startup (Popularity: ): SEATTLE - January 04, 2018 -- Today, AngelMD’s Catalyst I LP announced it has invested in Artoss, Inc. Artoss is a bone biologic company focused on improving bone grafting technology through a combination of nanotechnology and biology. This is AngelMD's second investment into the company, following a combined syndicate round in Q1 of 2016.With traditional bone grafts, there are numerous risks, including rejection of the grafting material and infection of ...
IBM Breakthrough Captures High Speed Measurements of Individual Atoms (Popularity: ): Today IBM (NYSE: IBM) researchers published a breakthrough technique in the peer-reviewed journal Science that measures how long a single atom can hold information, and giving scientists the ability to record, study and "visualize" extremely fast phenomena inside these atoms. Just as the first motion pictures conveyed movement through high-speed photography, scientists at IBM Research – Almaden are using the Scanning Tunneling Microscope like a high-speed camera to record the ...
Bacteria Pervasively Contaminating Chinese Drywall Conclusively Identified (Popularity: ): RealTime Laboratories, LLC announced today significant new findings regarding pervasive bacterial presence unique to contaminated drywall. RealTime has identified specific bacteria found only in symptomatic drywall and not in normal domestic drywall that are viable, pervasive and produce hydrogen sulfide and reduced sulfur gases under conditions similar to those found in residences. Cultures developed by RealTime using symptomatic contaminated drywall demonstrated a bacterial mat formation, generated copious amounts of hydrogen ...
National Semiconductor Introduces Industry's Lowest Nanopower Op Amp (Popularity: ): A new nanopower operational amplifier (op amp) from National Semiconductor Corp. (NYSE: NSM) provides the industry's lowest power consumption at 552 nanowatts (nW), with guaranteed operation down to 1.6V. The PowerWise(R) LPV521 extends battery life in portable equipment and low power applications including wireless remote sensors, power-line monitoring, and micropower oxygen and gas sensors.The LPV521 features a supply voltage range from 1.6V to 5.5V with a maximum supply current of ...
Kornberg Associates | Architects Selected to Develop Design for New Stanford University Imaging Center (Popularity: ): Kornberg Associates | Architects has been selected by Stanford University to design a new Cognitive & Neurobiological Imaging Center. Ken Kornberg, president and founder, made the announcement. The firm has worked with Stanford University since 1980 and has completed 20 projects over the past 30 years, one of which is the two-story, 32,000 square-foot office building for the Stanford Linear Accelerator. They are also working on the new three-story 35,000 ...

Press release home snapshot 


Related Business 
The RNAi Web (Popularity: ): The RNAi Web - Resource center for RNA interference technology. It offers scientific and technical information on RNAi technology, guidelines and tips on siRNA design, and also collects RNAi related web resources
The Quark Group (Popularity: ): The Quark Group sends out exclusive promotions and information to VIP customer by way of The Quark Group email promotions newsletter. Sign up today for all the best from The Quark Group. Quark Shoes' online shoe store carries women's shoes and men's shoes from brands such as Clarks, Skechers, Rockport, Ecco and more.
Indian Patent Global Services (Popularity: ): Indian Patent Global Services, is a Patent Attorney Firm, practicing exclusively covering search, drafting, and filing of patent application, prosecution, opposition, appeal and other related services. Having more than 40 years of experience in the industry leading manufacturing operations, engineering and R&D projects coupled with strong technical understanding of science and law, my firm would be in the best position to represent you in filing for patents in India. It ...
Sirna Therapeutics (Popularity: ): Develops ribozyme-based pharmaceuticals applicable to a wide range of human diseases. [Nasdaq: RNAI]
Patent Infringement (Popularity: ): Patent infringement is an everyday occurrence! A patent gives the patent owner the right to “exclude others from making, using, offering for sale, or selling” a product that includes the patented invention. Patent infringement occurs across all industries and all sectors of the economy. There are no Patent Police, so fighting patent infringement is the job of the company that owns the patent. While the Patent Office issues patents, it ...
Princeton World Wide Web, LLC. (Popularity: ): Help nurture ideas into patent applications then patents. Provides patent pending assistance, and workshops. One-on-one consultations available during Summer and Fall only. Patent application writing year round.
EPO Patent Registration and Consulting Services (Popularity: ): EPO Patent Registration and Consulting Services GmbH (EUROPEAN PATENT REGISTRATION) is a patent registration firm in Munich, Germany, of patent attorneys and involved experts providing services related to patents in Europe such as: patent search, patent filling, patent prosecution and registration of patent applications for obtaining of European Patent.
Molecula Research Laboratories, LLC (Popularity: ): Supplies high quality/cost effective DNA/RNA synthesis, dual labeled probes, various modifications and RNAi oligonucleotides. Specializes in design of siRNA and Antisense for gene function solutions.
Molecula Research Laboratories, LLC (Popularity: ): Supplies high quality/cost effective DNA/RNA synthesis, dual labeled probes, various modifications and RNAi oligonucleotides. Specializes in design of siRNA and Antisense for gene function solutions.
Ramdev Chemical Pvt. Ltd. (Popularity: ): Ramdev Chemicals Pvt. Ltd. is one of the fastest growing Pharmaceutical Bulk Drugs, Drug Intermediates, Speciality Chemicals & Custom Synthesis molecules manufacturing company in India. Our plant is located in India with a full fledge manufacturing facilities as listed. We have very strong team of Technocrats & Technical People engaged mainly into the New Molecules Development.